Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D82DMK
|
|||
| Drug Name |
LM11A-31
|
|||
| Synonyms |
N-[2-(Morpholin-4-yl)ethyl]-L-isoleucinamide; 1243259-19-9; (2S,3S)-2-amino-3-methyl-N-(2-morpholin-4-ylethyl)pentanamide; 102562-74-3; SCHEMBL1723692; DTXSID50595097; ZINC4239960; (2s,3s)-2-amino-3-methyl-N-(2-morpholinoethyl) pentanamide; (2S,3S)-2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide; (2S,3S)-2-Amino-3-methyl-N-(2-morpholinoethyl)pentanamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 1/2 | [1] | |
| Company |
PharmatrophiX Menlo Park, CA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C12H25N3O2
|
|||
| Canonical SMILES |
CCC(C)C(C(=O)NCCN1CCOCC1)N
|
|||
| InChI |
1S/C12H25N3O2/c1-3-10(2)11(13)12(16)14-4-5-15-6-8-17-9-7-15/h10-11H,3-9,13H2,1-2H3,(H,14,16)/t10-,11-/m0/s1
|
|||
| InChIKey |
YNMUTYLWSRFTPX-QWRGUYRKSA-N
|
|||
| CAS Number |
CAS 1243259-19-9
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Low-affinity nerve growth factor receptor (NGFR) | Target Info | Modulator | [2] |
| KEGG Pathway | Ras signaling pathway | |||
| Rap1 signaling pathway | ||||
| Cytokine-cytokine receptor interaction | ||||
| PI3K-Akt signaling pathway | ||||
| Neurotrophin signaling pathway | ||||
| Transcriptional misregulation in cancer | ||||
| Pathway Interaction Database | p75(NTR)-mediated signaling | |||
| Neurotrophic factor-mediated Trk receptor signaling | ||||
| Reactome | Axonal growth inhibition (RHOA activation) | |||
| NRAGE signals death through JNK | ||||
| p75NTR negatively regulates cell cycle via SC1 | ||||
| Regulated proteolysis of p75NTR | ||||
| NADE modulates death signalling | ||||
| NRIF signals cell death from the nucleus | ||||
| p75NTR recruits signalling complexes | ||||
| NF-kB is activated and signals survival | ||||
| Axonal growth stimulation | ||||
| WikiPathways | Spinal Cord Injury | |||
| BDNF signaling pathway | ||||
| Signalling by NGF | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03069014) Study of LM11A-31-BHS in Mild-moderate AD Patients. U.S. National Institutes of Health. | |||
| REF 2 | Modulation of the p75 neurotrophin receptor using LM11A-31 prevents diabetes-induced retinal vascular permeability in mice via inhibition of inflammation and the RhoA kinase pathway. Diabetologia. 2019 Aug;62(8):1488-1500. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.